PneumoniaNCT07574866
A Retrospective Study on Clinical Characteristics and Outcomes of Patients With Pneumonia
An observational study of Pneumonia, run by Zhonghao Fang at 1 site in China.
Trial summary
Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pneumonia
- How many people
- 500 participants
- Where
- 1 siteChina
- Study dates
- Apr 2026to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: From April 2023 to April 2026, all adult patients who were hospitalized due to pneumonia and met the diagnostic criteria
Who may be able to join
- Age ≥ 18 years old;
- Meet the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging);
- Have a positive result from pathogen testing;
- Time from onset to admission ≤ 72 hours (to ensure being in the acute phase of the disease);
- Sign a written informed consent form.
- A diagnosis of "severe pneumonia" can be made if one of the main criteria or ≥ 3 of the secondary criteria are met.
Show all 17Show fewer
- Main criteria:
- ① Tracheal intubation requiring mechanical ventilation
- ② Need for vasoactive drugs after active fluid resuscitation for septic shock
- Secondary criteria:
- Respiratory rate ≥ 30 breaths/min
- PaO₂/FiO₂ ≤ 250 mm Hg
- Multiple lobe infiltrates
- Confusion and/or disorientation ⑤ Blood urea nitrogen ≥ 20 mg/dL
- ⑥ Leukopenia (WBC < 4×10⁹/L)
- Thrombocytopenia (PLT < 100×10⁹/L)
- Decreased body temperature (central body temperature < 36 ℃) ⑨ Hypotension requiring fluid resuscitation
Who cannot join
- 1) Patients with severely lacking medical records;
- 2) Those whose main manifestations are other non-infectious diseases (such as pulmonary edema, lung cancer, pulmonary embolism, etc.); 3) Those whose main diagnosis is active pulmonary tuberculosis, non-infectious interstitial lung disease, etc.; 4) Patients considered not applicable by the researchers.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou
Liang Peng, Doctor, 86-020-85959142, pl_206@126.com
About this study
Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging and the frequent emergence of drug-resistant bacteria; in China, severe pneumonia accounts for a striking 13.58% to 20.05% of hospitalized cases. In recent years, shifts in the pathogen spectrum (e.g., COVID-19, influenza A) and patient demographic characteristics have posed new challenges for clinical management. However, existing studies mostly focus on single pathogens or specific populations (e.g., ICU patients), lacking systematic analyses of the full-disease course characteristics of general hospitalized pneumonia patients. Furthermore, in the post-pandemic era, the clinical phenotypes, treatment responses, and prognostic factors of pneumonia may have evolved, necessitating evidence-based support from real-world data. This study aims to conduct a retrospective analysis to clarify the epidemiological characteristics, etiological distribution, and prognostic factors influencing current hospitalized pneumonia patients, thereby providing a basis for optimizing diagnosis and treatment strategies.
- Conditions
- Pneumonia
- Keywords
- pneumonia
- Medical subject headings
- Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| pneumonia | pneumonia |
What is being measured
The primary outcome is the main question the study is designed to answer.
28-day all-cause mortality rate
Measured: 28 days after admission
Secondary outcomes (8)
Demographic characteristics
Demographic data (age, sex, etc.)
Measured: 28 days after admission
Comorbidities
Comorbidities, such as chronic obstructive pulmonary disease (COPD), diabetes mellitus, and cardiovascular diseases.
Measured: 28 days after admission
Symptomatic manifestations
Symptomatic manifestations (e.g., fever, cough, dyspnea)
Measured: 28 days after admission
Laboratory tests
Laboratory tests (including blood routine, liver and kidney function, etc.)
Measured: 28 days after admission
Imaging Examination
Imaging Examination: Radiological manifestations and image data from chest X-ray or CT scans
Measured: 28 days after admission
ICU Length of Stay
Measured: 28 days after admission
Duration of Mechanical Ventilation
Measured: 28 days after admission
Length of Hospital Stay
Measured: 28 days after admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2026
- Study startApr 2026 (estimated)
- Primary completionOct 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhonghao Fang
- Sponsor type
- University, hospital or other
- Collaborators
- Fifth Affiliated Hospital of Guangzhou Medical University
- Responsible party
- Sponsor-investigator, Zhonghao Fang, Guangzhou Medical University
- Investigators
- Zifeng Yang, Study director, The First Affiliated Hospital of Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07574866
- Sponsor's protocol ID
- P-2026-003
- Status last verified
- Apr 2026
- First submitted
- 28 Apr 2026
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Due to concerns over patient privacy and confidentiality issues, the individual patient data (IPD) cannot be shared.
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Retrospective Study on Clinical Characteristics and Outcomes of Patients With Pneumonia
- ClinicalTrials.gov ID
- NCT07574866
- Acronym / sponsor ID
- P-2026-003
- Conditions
- Pneumonia
- Keywords
- pneumonia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Zhonghao FangUniversity, hospital or other
- Collaborators
- Fifth Affiliated Hospital of Guangzhou Medical University
- Study start
- Apr 2026 (estimated)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 8 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging and the frequent emergence of drug-resistant bacteria; in China, severe pneumonia accounts for a striking 13.58% to 20.05% of hospitalized cases. In recent years, shifts in the pathogen spectrum (e.g., COVID-19, influenza A) and patient demographic characteristics have posed new challenges for clinical management. However, existing studies mostly focus on single pathogens or specific populations (e.g., ICU patients), lacking systematic analyses of the full-disease course characteristics of general hospitalized pneumonia patients. Furthermore, in the post-pandemic era, the clinical phenotypes, treatment responses, and prognostic factors of pneumonia may have evolved, necessitating evidence-based support from real-world data. This study aims to conduct a retrospective analysis to clarify the epidemiological characteristics, etiological distribution, and prognostic factors influencing current hospitalized pneumonia patients, thereby providing a basis for optimizing diagnosis and treatment strategies.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| pneumonia | – | –pneumonia |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- From April 2023 to April 2026, all adult patients who were hospitalized due to pneumonia and met the diagnostic criteria
Key inclusion criteria (17 listed)
- Age ≥ 18 years old;
- Meet the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging);
- Have a positive result from pathogen testing;
- Time from onset to admission ≤ 72 hours (to ensure being in the acute phase of the disease);
- Sign a written informed consent form.
Key exclusion criteria (2 listed)
- 2) Those whose main manifestations are other non-infectious diseases (such as pulmonary edema, lung cancer, pulmonary embolism, etc.); 3) Those whose main diagnosis is active pulmonary tuberculosis, non-infectious interstitial lung disease, etc.; 4) Patients considered not applicable by the researchers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
28-day all-cause mortality rate
Time frame: 28 days after admission
8 secondary outcomes
Demographic characteristics
Time frame: 28 days after admission
Comorbidities
Time frame: 28 days after admission
Symptomatic manifestations
Time frame: 28 days after admission
Laboratory tests
Time frame: 28 days after admission
Imaging Examination
Time frame: 28 days after admission
ICU Length of Stay
Time frame: 28 days after admission
Duration of Mechanical Ventilation
Time frame: 28 days after admission
Length of Hospital Stay
Time frame: 28 days after admission
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Individual participant dataSharing planned: No. Due to concerns over patient privacy and confidentiality issues, the individual patient data (IPD) cannot be shared.
Related trials for Pneumonia
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Zifeng Yang study director
The First Affiliated Hospital of Guangzhou Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumonia, run by Zhonghao Fang at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Liang Peng, Doctor (86-020-85959142, pl_206@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
28-day all-cause mortality rate (time frame: 28 days after admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.